Global Risk-Based Monitoring Software Market – Industry Trends and Forecast to 2029

Global Risk-Based Monitoring Software Market, By Type (Enterprise RBM Software, Site RBM Software), Component (Software, Services), Delivery Mode (Web-Based (On-Demand), Licensed Enterprise (On-Premise), Cloud-Based (SAAS)), End-User (Pharmaceutical and Biopharmaceutical Companies, Contract Research Organizations (CROS), Medical Device Companies, Other) – Industry Trends and Forecast to 2029

Risk-Based Monitoring Software Market Analysis and Size

The risk-based monitoring software market is expected to grow over the next few years due to the time and cost efficiency of risk-based monitoring software. Risk-based monitoring software gives clinical team’s access to actionable datasets to support clinical programs and research. The government and regulatory bodies mandate the importance of reviewing clinical trials to avoid errors and mistakes. The discovery of new diseases and the increasing number of clinical trials and studies indicate a higher growth path for market evaluation.

Data Bridge Market Research analyses a growth in the global risk-based monitoring software market in the forecast period 2022-2029. The expected CAGR of the global risk-based monitoring software market is tend to be around 13.7% in the mentioned forecast period. The market was valued at USD 278 million in 2021, and it would grow upto USD 776.48 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Risk-Based Monitoring Software Market Scope and Segmentation

Market Definition

Risk-based monitoring software is clinical trial monitoring software that meets regulatory requirements. However, it is far from patient data's source data validation (SDV). Identify signals using a variety of platforms, tools, and dashboards used to resolve issues related to clinical trial safety, data integrity, and compliance. This risk-based monitoring software helps you focus on risk-free research on high-value tasks. Thus, with the onset of this software, the market will be beneficial. Hence, it is helpful for market growth.

Global Risk-Based Monitoring Software Market Dynamics

Drivers

• Increasing Demand for Web-Based Delivery Mode

The web-based (on-demand) segment is expected to hold a large market share in the risk-based monitoring software industry. This growth is due to the increasing implementation of web-based risk-based monitoring solutions due to increased scalability, reduced maintenance costs, customizability, and ease of integration. In addition, the web-based delivery mode is expected to contribute to productivity improvement and work efficiency improvement, further supporting the growth of the market. These factors are expected to contribute to overall market growth during the forecast period. Thus, it helps drive risk-based monitoring software market growth.

• Increasing Demand For Clinical Trials

The rising surge in clinical trials is a driving factor that leads to market growth. This is due to the ongoing demand for drug development amid a rise in the incidence of chronic diseases. For instance, in April 2021, Veeva Systems announced a collaboration with Parexel to leverage innovation to accelerate clinical trials. Through this partnership, Parexel will standardize Veeva's suite of clinical applications while gaining early access to Veeva's clinical innovations, such as trials (DCTs). These developments are expected to have a positive impact on the growth of the risk-based monitoring software industry during the forecast period.

Opportunities

• Launch of new versions of risk-based monitoring software

Key market players are focusing on deploying updated versions of risk-based monitoring software. This could increase the demand for risk-based monitoring software in pharmaceutical companies, biopharmacy companies, CROs, and medical device companies. For instance, in 2018, Bioclinica announced the SMART Technology Suite, which combines medical imaging, electronic data acquisition (EDC), and interactive response technology (IRT).

• Beneficial Factors Associated with the Software

The several beneficial effects of the risk-based monitoring software lead to create more opportunities for the market. Risk-based monitoring software can reduce errors, improve analytics, timely results, and reduce costs.

 Restraints/Challenges

• High Costs

The risk-based monitoring software is definitely helping to outgrow the market size, but one factor limiting the growth is the high price of the software. It is costly, and thus it is not applicable everytime to use it tremendously.

This global risk-based monitoring software market provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global risk-based monitoring software market, contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Risk-Based Monitoring Software Market

The COVID-19 has left an unprecedented global public health crisis that has impacted practically every business, and its long-term repercussions are expected to influence on industry growth during the forecast period. Our ongoing research enhances our research approach to guarantee that fundamental COVID-19 concerns and potential solutions are included.

COVID19 has significantly increased the demand for medical supplies such as personal protective equipment such as masks, gloves and goggles. As the number of cases of COVID 19 increases worldwide, there is an increasing need for medicines from both medical  professionals and civilians for preventative measures. Manufacturers of these products have the opportunity to take advantage of this growing demand for medical supplies to ensure an adequate and continuous supply of the personal protective equipment market. Given these factors, COVID 19 is expected to impact the risk-based monitoring software market significantly.

Global Risk-Based Monitoring Software Market Scope

The global risk-based monitoring software market is segmented on the basis of type, component, delivery mode, and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Enterprise RBM Software
• Site RBM Software

Component

• Software
• Services

Delivery Mode

• Web-Based (On-Demand)
• Licensed Enterprise (On-Premise)
• Cloud-Based (SAAS)

End-User

• Pharmaceutical and Biopharmaceutical Companies
• Contract Research Organizations (CROS)
• Medical Device Companies
• Other

Risk-Based Monitoring Software Market Regional Analysis/Insights

The global risk-based monitoring software market is analyzed and market size insights and trends are provided by country, type, component, delivery mode, and end-user as referenced above.

The major countries covered in the risk-based monitoring software market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the risk-based monitoring software market due to the increasing number of pharmaceutical companies in the region.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the rising initiatives and prevalence of funds from government for clinical trials.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Risk-Based Monitoring Software Market Share Analysis

The risk-based monitoring software market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to budesonide inhaler system market.

Key players operating in the global risk-based monitoring software market include:

• Oracle (US)
• Medidata Solutions, Inc. (US)
• Parexel International Corporation. (US)
• Bioclinica (US)
• Bio-Optronics, Inc. (US)
• IBM Corporation (US).
• Veeva Systems (US)
• DSG, Inc. (US)
• MasterControl, Inc. (US)
• Forte Research Systems India Pvt Ltd (India)
• Mednet (India)
• ArisGlobal LLC. (US)
• Anju Software, Inc. (US)
• Techsol Corporation (US)
• OpenClinica, LLC (US)
• Signant Health (US)
• Labcorp Drug Development(US)